NCT02507388View on ClinicalTrials.gov

Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

PHASE2CompletedINTERVENTIONAL

Enrollment

51

Participants

Timeline

Start Date

August 24, 2015

Primary Completion Date

September 6, 2016

Study Completion Date

September 6, 2016

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

DRUG

Brolucizumab 3 mg/50 μL

Administered as an intravitreal injection

DRUG

Brolucizumab 6 mg/50 μL

Administered as an intravitreal injection

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Alcon Research

INDUSTRY